These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22990204)

  • 1. OSU-03012 interacts with lapatinib to kill brain cancer cells.
    Booth L; Cruickshanks N; Ridder T; Chen CS; Grant S; Dent P
    Cancer Biol Ther; 2012 Dec; 13(14):1501-11. PubMed ID: 22990204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells.
    Hamed HA; Tavallai S; Grant S; Poklepovic A; Dent P
    J Cell Physiol; 2015 Jan; 230(1):131-9. PubMed ID: 24911215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
    Mitchell C; Yacoub A; Hossein H; Martin AP; Bareford MD; Eulitt P; Yang C; Nephew KP; Dent P
    Cancer Biol Ther; 2010 Nov; 10(9):903-17. PubMed ID: 20855960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation.
    Martin AP; Miller A; Emad L; Rahmani M; Walker T; Mitchell C; Hagan MP; Park MA; Yacoub A; Fisher PB; Grant S; Dent P
    Mol Pharmacol; 2008 Sep; 74(3):807-22. PubMed ID: 18544666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1.
    Cruickshanks N; Hamed HA; Bareford MD; Poklepovic A; Fisher PB; Grant S; Dent P
    Mol Pharmacol; 2012 May; 81(5):748-58. PubMed ID: 22357666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OSU-03012 suppresses GRP78/BiP expression that causes PERK-dependent increases in tumor cell killing.
    Booth L; Cazanave SC; Hamed HA; Yacoub A; Ogretmen B; Chen CS; Grant S; Dent P
    Cancer Biol Ther; 2012 Feb; 13(4):224-36. PubMed ID: 22354011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy.
    Cruickshanks N; Hamed HA; Booth L; Tavallai S; Syed J; Sajithlal GB; Grant S; Poklepovic A; Dent P
    Cancer Biol Ther; 2013 Oct; 14(10):982-96. PubMed ID: 24025251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95.
    Park MA; Zhang G; Mitchell C; Rahmani M; Hamed H; Hagan MP; Yacoub A; Curiel DT; Fisher PB; Grant S; Dent P
    Mol Cancer Ther; 2008 Sep; 7(9):2633-48. PubMed ID: 18790746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy.
    Martin AP; Mitchell C; Rahmani M; Nephew KP; Grant S; Dent P
    Cancer Biol Ther; 2009 Nov; 8(21):2084-96. PubMed ID: 19823038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.
    Xia W; Husain I; Liu L; Bacus S; Saini S; Spohn J; Pry K; Westlund R; Stein SH; Spector NL
    Cancer Res; 2007 Feb; 67(3):1170-5. PubMed ID: 17283152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species.
    Walker T; Mitchell C; Park MA; Yacoub A; Rahmani M; Häussinger D; Reinehr R; Voelkel-Johnson C; Fisher PB; Grant S; Dent P
    Mol Cancer Ther; 2010 May; 9(5):1378-95. PubMed ID: 20442308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors.
    Wang YC; Kulp SK; Wang D; Yang CC; Sargeant AM; Hung JH; Kashida Y; Yamaguchi M; Chang GD; Chen CS
    Cancer Res; 2008 Apr; 68(8):2820-30. PubMed ID: 18413750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells.
    Park MA; Yacoub A; Rahmani M; Zhang G; Hart L; Hagan MP; Calderwood SK; Sherman MY; Koumenis C; Spiegel S; Chen CS; Graf M; Curiel DT; Fisher PB; Grant S; Dent P
    Mol Pharmacol; 2008 Apr; 73(4):1168-84. PubMed ID: 18182481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells.
    Yacoub A; Park MA; Hanna D; Hong Y; Mitchell C; Pandya AP; Harada H; Powis G; Chen CS; Koumenis C; Grant S; Dent P
    Mol Pharmacol; 2006 Aug; 70(2):589-603. PubMed ID: 16622074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.
    Booth L; Roberts JL; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
    Cancer Biol Ther; 2018 Mar; 19(3):239-247. PubMed ID: 29333953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: a role for Nck1 but not Nck2.
    West NW; Garcia-Vargas A; Chalfant CE; Park MA
    BMC Cancer; 2013 May; 13():256. PubMed ID: 23706161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OSU-03012 and Viagra Treatment Inhibits the Activity of Multiple Chaperone Proteins and Disrupts the Blood-Brain Barrier: Implications for Anti-Cancer Therapies.
    Booth L; Roberts JL; Tavallai M; Nourbakhsh A; Chuckalovcak J; Carter J; Poklepovic A; Dent P
    J Cell Physiol; 2015 Aug; 230(8):1982-98. PubMed ID: 25736380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pazopanib and HDAC inhibitors interact to kill sarcoma cells.
    Tavallai S; Hamed HA; Grant S; Poklepovic A; Dent P
    Cancer Biol Ther; 2014 May; 15(5):578-85. PubMed ID: 24556916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer.
    Singla S; Pippin JA; Drebin JA
    Oncol Rep; 2012 Dec; 28(6):2211-6. PubMed ID: 23007710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.
    Leow CC; Chesebrough J; Coffman KT; Fazenbaker CA; Gooya J; Weng D; Coats S; Jackson D; Jallal B; Chang Y
    Mol Cancer Ther; 2009 Aug; 8(8):2131-41. PubMed ID: 19671750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.